(Q33843948)

29 July 2017

1 reference

title

Diffuse panbronchiolitis--pathophysiology and treatment mechanisms (English)

1 reference

29 July 2017

1 reference

Yanagihara K

1

1 reference

29 July 2017

Kadoto J

series ordinal

2

1 reference

29 July 2017

Kohno S

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2001

1 reference

International Journal of Antimicrobial Agents

29 July 2017

published in

1 reference

29 July 2017

volume

18 Suppl 1

1 reference

29 July 2017

page(s)

S83-7

1 reference

Diffuse panbronchiolitis. A disease of the transitional zone of the lung

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Diffuse panbronchiolitis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Neutrophil attractant/activation protein-1 (NAP-1 [interleukin-8]).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

[Study on azithromycin in treatment of diffuse panbronchiolitis]

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900403-4

7 January 2021

10.1016/S0924-8579(01)00403-4

Identifiers

DOI

1 reference

29 July 2017

1 reference